Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands

Annals of Hematology

Volumn 94, Issue 1, 2015, Pages 45-56

  van den Broek, Esther C ^a,g   Oerlemans, Simone ^a,b   Nijziel, Marten R ^c   Posthuma, Eduardus F M ^d,e   Coebergh, Jan Willem W ^a,f   van de Poll Franse, Lonneke V ^a,b  

^a The Netherlands   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d REINIER DE GRAAF HOSPITAL   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Eindhoven Cancer Registry   (Netherlands)

Author keywords

Chronic lymphocytic leukemia; Health related quality of life; Population based; Registry; Therapy

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL;

AGED; COHORT ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; REGISTER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; QUALITY OF LIFE; REGISTRIES;

EID: 84925284587     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2161-6     Document Type: Article

References (31)

1. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM, Berrino F, Group HW (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116(19):3724–3734. doi:10.1182/blood-2010-05-282632
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
3. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C, Muntanola A, Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E (2009) Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 114(10):2044–2050
4. van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF (2011) Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989-2008. Eur J Cancer 48(6):889–895
5. CLL-Trialists'-Collaborative-Group (1999) Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 91(10):861–868
6. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174
7. Eichhorst B, Goede V, Hallek M (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50(2):171–178
8. Smolej L (2012) Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Curr Pharm Des 18(23):3399–3405
9. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. doi:10.1056/NEJMoa1313984
10. Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M (2007) Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol 25(13):1722–1731
11. Else M, Cocks K, Crofts S, Wade R, Richards SM, Catovsky D, Smith AG (2012) Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma 53(7):1289–1298
12. Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R (2004) Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 72(6):381–389
13. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B (2008) Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 44(11):1497–1506
14. Shanafelt T (2013) Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematol Educ Prog Am Soc Hematol Am Soc Hematol 2013:158–167. doi:10.1182/asheducation-2013.1.158
15. Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G, Scandinavian Prostate Cancer Group Study N (2009) Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 55(2):422–430. doi:10.1016/j.eururo.2008.08.054
16. Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology (ed 3rd). World Health Organisation, Geneva
17. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, Vingerhoets A, Coebergh JW, de Vries J, Essink-Bot ML, Mols F (2011) The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
19. Snaith RP, Zigmond AS (1986) The hospital anxiety and depression scale. Br Med J (Clin Res Ed) 292(6516):344
20. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370
21. Crespi CM, Ganz PA, Petersen L, Castillo A, Caan B (2008) Refinement and psychometric evaluation of the impact of cancer scale. J Natl Cancer Inst 100(21):1530–1541
22. Zebrack BJ, Ganz PA, Bernaards CA, Petersen L, Abraham L (2006) Assessing the impact of cancer: development of a new instrument for long-term survivors. Psycho-Oncology 15(5):407–421
23. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163
24. van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, Taphoorn MJ, Aaronson NK (2010) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675
25. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96
26. Oerlemans S, Mols F, Issa DE, Pruijt JH, Peters WG, Lybeert M, Zijlstra W, Coebergh JW, van de Poll-Franse LV (2013) A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica 98(3):479–486
27. Oerlemans S, Mols F, Nijziel MR, Lybeert M, van de Poll-Franse LV (2011) The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol 90(9):993–1004
28. Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88(9):803–816
29. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG (2007) Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 139(2):255–264
30. CLL-Working-Group http://www.icr.ac.uk/research/research_divisions/Molecular_Pathology/CLL4_trial/19521.pdf
31. Husson O, Mols F, van de Poll-Franse LV (2011) The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol 22(4):761–772